FMR1 and the Continuum of Primary Ovarian Insufficiency

 

 Buy Article Permissions and Reprints

ABSTRACT

Spontaneous 46,XX primary ovarian insufficiency (POI) is a term that describes ovarian dysfunction resulting in a range of abnormalities, from infertility to early menopause as the end stage (overt POI). The most common known genetic cause of 46,XX POI is the expansion of a CGG repeat to 55 to 199 copies in the 5′ untranslated region in the X-linked FMR1 gene. This “premutation” is associated with overt POI (FXPOI) in ~20% of carrier women. Greater than 200 CGG copies results in methylation of the CGG repeats and subsequent silencing of the FMR1 gene, causing fragile X syndrome. This “full” mutation is not associated with FXPOI. Even in the absence of overt FXPOI, women who carry the premutation may exhibit ovarian dysfunction along a continuum of severity. Evidence also suggests that the severity of FXPOI depends on the CGG repeat length, background modifier genes, and environmental factors (e.g., smoking). This review explores the range of ovarian dysfunction, the mechanisms behind the dysfunction, and the reasons for the variability in presentation in women who carry the FMR1 premutation. Understanding the mechanisms responsible for development of FXPOI is paramount to providing these women with the best overall health care.

REFERENCES

• 1 Nelson L M. Clinical practice. Primary ovarian insufficiency.  N Engl J Med. 2009;  360 (6) 606-614
  CrossrefPubMedGoogle Scholar
• 2 Hubayter Z R, Popat V, Vanderhoof V H et al.. A prospective evaluation of antral follicle function in women with 46,XX spontaneous primary ovarian insufficiency.  Fertil Steril. 2010;  94 (5) 1769-1774
  CrossrefPubMedGoogle Scholar
• 3 Gallagher J C. Effect of early menopause on bone mineral density and fractures.  Menopause. 2007;  14 (3 Pt 2) 567-571
  CrossrefPubMedGoogle Scholar
• 4 Jacobsen B K, Knutsen S F, Fraser G E. Age at natural menopause and total mortality and mortality from ischemic heart disease: the Adventist Health Study.  J Clin Epidemiol. 1999;  52 (4) 303-307
  CrossrefPubMedGoogle Scholar
• 5 Mondul A M, Rodriguez C, Jacobs E J, Calle E E. Age at natural menopause and cause-specific mortality.  Am J Epidemiol. 2005;  162 (11) 1089-1097
  CrossrefPubMedGoogle Scholar
• 6 Popat V B, Calis K A, Vanderhoof V H et al.. Bone mineral density in estrogen-deficient young women.  J Clin Endocrinol Metab. 2009;  94 (7) 2277-2283
  CrossrefPubMedGoogle Scholar
• 7 Allingham-Hawkins D J, Babul-Hirji R, Chitayat D et al.. Fragile X premutation is a significant risk factor for premature ovarian failure: the International Collaborative POF in Fragile X study—preliminary data.  Am J Med Genet. 1999;  83 (4) 322-325
  CrossrefPubMedGoogle Scholar
• 8 Sherman S L. Premature ovarian failure in the fragile X syndrome.  Am J Med Genet. 2000;  97 (3) 189-194
  CrossrefPubMedGoogle Scholar
• 9 Sherman S T. FMR1 premutation: a leading cause of inherited ovarian dysfunction. In: Arrieta I, Penagarikano O, Télez M, eds. Fragile Sites: New Discoveries and Changing Perspectives. Hauppauge, NY: Nova Science Publishers; 2007: 299-320
  Google Scholar
• 10 Crawford D C, Acuña J M, Sherman S L. FMR1 and the fragile X syndrome: human genome epidemiology review.  Genet Med. 2001;  3 (5) 359-371
  CrossrefPubMedGoogle Scholar
• 11 Cronister A, Teicher J, Rohlfs E M, Donnenfeld A, Hallam S. Prevalence and instability of fragile X alleles: implications for offering fragile X prenatal diagnosis.  Obstet Gynecol. 2008;  111 (3) 596-601
  CrossrefPubMedGoogle Scholar
• 12 Allen E G, Sullivan A K, Marcus M et al.. Examination of reproductive aging milestones among women who carry the FMR1 premutation.  Hum Reprod. 2007;  22 (8) 2142-2152
  CrossrefPubMedGoogle Scholar
• 13 Hundscheid R D, Braat D D, Kiemeney L A, Smits A P, Thomas C M. Increased serum FSH in female fragile X premutation carriers with either regular menstrual cycles or on oral contraceptives.  Hum Reprod. 2001;  16 (3) 457-462
  CrossrefPubMedGoogle Scholar
• 14 Murray A, Webb J, MacSwiney F, Shipley E L, Morton N E, Conway G S. Serum concentrations of follicle stimulating hormone may predict premature ovarian failure in FRAXA premutation women.  Hum Reprod. 1999;  14 (5) 1217-1218
  CrossrefPubMedGoogle Scholar
• 15 Rohr J, Allen E G, Charen K et al.. Anti-Mullerian hormone indicates early ovarian decline in fragile X mental retardation (FMR1) premutation carriers: a preliminary study.  Hum Reprod. 2008;  23 (5) 1220-1225
  CrossrefPubMedGoogle Scholar
• 16 Welt C K, Smith P C, Taylor A E. Evidence of early ovarian aging in fragile X premutation carriers.  J Clin Endocrinol Metab. 2004;  89 (9) 4569-4574
  CrossrefPubMedGoogle Scholar
• 17 Murray A, Ennis S, MacSwiney F, Webb J, Morton N E. Reproductive and menstrual history of females with fragile X expansions.  Eur J Hum Genet. 2000;  8 (4) 247-252
  CrossrefPubMedGoogle Scholar
• 18 Sullivan A K, Marcus M, Epstein M P et al.. Association of FMR1 repeat size with ovarian dysfunction.  Hum Reprod. 2005;  20 (2) 402-412
  PubMedGoogle Scholar
• 19 Bell M V, Hirst M C, Nakahori Y et al.. Physical mapping across the fragile X: hypermethylation and clinical expression of the fragile X syndrome.  Cell. 1991;  64 (4) 861-866
  CrossrefPubMedGoogle Scholar
• 20 Sutcliffe J S, Nelson D L, Zhang F et al.. DNA methylation represses FMR-1 transcription in fragile X syndrome.  Hum Mol Genet. 1992;  1 (6) 397-400
  CrossrefPubMedGoogle Scholar
• 21 Tassone F, Hagerman P J. Expression of the FMR1 gene.  Cytogenet Genome Res. 2003;  100 (1–4) 124-128
  CrossrefPubMedGoogle Scholar
• 22 Sherman S, Pletcher B A, Driscoll DACINGMN. Fragile X syndrome: diagnostic and carrier testing.  Genet Med. 2005;  7 (8) 584-587
  CrossrefPubMedGoogle Scholar
• 23 Fernandez-Carvajal I, Lopez Posadas B, Pan R, Raske C, Hagerman P J, Tassone F. Expansion of an FMR1 grey-zone allele to a full mutation in two generations.  J Mol Diagn. 2009;  11 (4) 306-310
  CrossrefPubMedGoogle Scholar
• 24 Terracciano A, Pomponi M G, Marino G M et al.. Expansion to full mutation of a FMR1 intermediate allele over two generations.  Eur J Hum Genet. 2004;  12 (4) 333-336
  CrossrefPubMedGoogle Scholar
• 25 Allen E G, He W, Yadav-Shah M, Sherman S L. A study of the distributional characteristics of FMR1 transcript levels in 238 individuals.  Hum Genet. 2004;  114 (5) 439-447
  CrossrefPubMedGoogle Scholar
• 26 García-Alegría E, Ibáñez B, Mínguez M et al.. Analysis of FMR1 gene expression in female premutation carriers using robust segmented linear regression models.  RNA. 2007;  13 (5) 756-762
  CrossrefPubMedGoogle Scholar
• 27 Kenneson A, Zhang F, Hagedorn C H, Warren S T. Reduced FMRP and increased FMR1 transcription is proportionally associated with CGG repeat number in intermediate-length and premutation carriers.  Hum Mol Genet. 2001;  10 (14) 1449-1454
  CrossrefPubMedGoogle Scholar
• 28 Tassone F, Beilina A, Carosi C et al.. Elevated FMR1 mRNA in premutation carriers is due to increased transcription.  RNA. 2007;  13 (4) 555-562
  CrossrefPubMedGoogle Scholar
• 29 Tassone F, Hagerman R J, Taylor A K, Gane L W, Godfrey T E, Hagerman P J. Elevated levels of FMR1 mRNA in carrier males: a new mechanism of involvement in the fragile-X syndrome.  Am J Hum Genet. 2000;  66 (1) 6-15
  CrossrefPubMedGoogle Scholar
• 30 Tassone F, Hagerman R J, Taylor A K et al.. Clinical involvement and protein expression in individuals with the FMR1 premutation.  Am J Med Genet. 2000;  91 (2) 144-152
  CrossrefPubMedGoogle Scholar
• 31 Peprah E, He W, Allen E, Oliver T, Boyne A, Sherman S L. Examination of FMR1 transcript and protein levels among 74 premutation carriers.  J Hum Genet. 2010;  55 (1) 66-68
  CrossrefPubMedGoogle Scholar
• 32 Hundscheid R D, Smits A P, Thomas C M, Kiemeney L A, Braat D D. Female carriers of fragile X premutations have no increased risk for additional diseases other than premature ovarian failure.  Am J Med Genet A. 2003;  117A (1) 6-9
  CrossrefPubMedGoogle Scholar
• 33 Hagerman P J, Greco C M, Hagerman R J. A cerebellar tremor/ataxia syndrome among fragile X premutation carriers.  Cytogenet Genome Res. 2003;  100 (1-4) 206-212
  CrossrefPubMedGoogle Scholar
• 34 Lambalk C B, De Koning C H, Braat D D. The endocrinology of dizygotic twinning in the human.  Mol Cell Endocrinol. 1998;  145 (1–2) 97-102
  CrossrefPubMedGoogle Scholar
• 35 Fryns J P. The female and the fragile X. A study of 144 obligate female carriers.  Am J Med Genet. 1986;  23 (1–2) 157-169
  CrossrefPubMedGoogle Scholar
• 36 Turner G, Robinson H, Wake S, Martin N. Dizygous twinning and premature menopause in fragile X syndrome.  Lancet. 1994;  344 (8935) 1500
  PubMedGoogle Scholar
• 37 Vianna-Morgante A M, Costa S S. Premature ovarian failure is associated with maternally and paternally inherited premutation in Brazilian families with fragile X.  Am J Hum Genet. 2000;  67 (1) 254-255 author reply 256-258
  CrossrefPubMedGoogle Scholar
• 38 Sherman S L, Meadows K L, Ashley A E. Examination of factors that influence the expansion of the fragile X mutation in a sample of conceptuses from known carrier females.  Am J Med Genet. 1996;  64 (2) 256-260
  CrossrefPubMedGoogle Scholar
• 39 Ennis S, Ward D, Murray A. Nonlinear association between CGG repeat number and age of menopause in FMR1 premutation carriers.  Eur J Hum Genet. 2006;  14 (2) 253-255
  CrossrefPubMedGoogle Scholar
• 40 Tejada M I, García-Alegría E, Bilbao A et al.. Analysis of the molecular parameters that could predict the risk of manifesting premature ovarian failure in female premutation carriers of fragile X syndrome.  Menopause. 2008;  15 (5) 945-949
  CrossrefPubMedGoogle Scholar
• 41 Bodega B, Bione S, Dalprà L et al.. Influence of intermediate and uninterrupted FMR1 CGG expansions in premature ovarian failure manifestation.  Hum Reprod. 2006;  21 (4) 952-957
  PubMedGoogle Scholar
• 42 Bretherick K L, Fluker M R, Robinson W P. FMR1 repeat sizes in the gray zone and high end of the normal range are associated with premature ovarian failure.  Hum Genet. 2005;  117 (4) 376-382
  CrossrefPubMedGoogle Scholar
• 43 Gleicher N, Weghofer A, Oktay K, Barad D H. Correlation of triple repeats on the FMR1 (fragile X) gene to ovarian reserve: a new infertility test?.  Acta Obstet Gynecol Scand. 2009;  88 (9) 1024-1030
  CrossrefPubMedGoogle Scholar
• 44 Streuli I, Fraisse T, Ibecheole V, Moix I, Morris M A, de Ziegler D. Intermediate and premutation FMR1 alleles in women with occult primary ovarian insufficiency.  Fertil Steril. 2009;  92 (2) 464-470
  CrossrefPubMedGoogle Scholar
• 45 Bennett C E, Conway G S, Macpherson J N, Jacobs P A, Murray A. Intermediate sized CGG repeats are not a common cause of idiopathic premature ovarian failure.  Hum Reprod. 2010;  25 (5) 1335-1338
  CrossrefPubMedGoogle Scholar
• 46 Loesch D Z, Khaniani M S, Slater H R et al.. Small CGG repeat expansion alleles of FMR1 gene are associated with parkinsonism.  Clin Genet. 2009;  76 (5) 471-476
  CrossrefPubMedGoogle Scholar
• 47 Kraff J, Tang H T, Cilia R et al.. Screen for excess FMR1 premutation alleles among males with parkinsonism.  Arch Neurol. 2007;  64 (7) 1002-1006
  CrossrefPubMedGoogle Scholar
• 48 Kurz M W, Schlitter A M, Klenk Y et al.. FMR1 alleles in Parkinson's disease: relation to cognitive decline and hallucinations, a longitudinal study.  J Geriatr Psychiatry Neurol. 2007;  20 (2) 89-92
  CrossrefPubMedGoogle Scholar
• 49 Toft M, Aasly J, Bisceglio G et al.. Parkinsonism, FXTAS, and FMR1 premutations.  Mov Disord. 2005;  20 (2) 230-233
  CrossrefPubMedGoogle Scholar
• 50 Jin P, Zarnescu D C, Zhang F et al.. RNA-mediated neurodegeneration caused by the fragile X premutation rCGG repeats in Drosophila.  Neuron. 2003;  39 (5) 739-747
  CrossrefPubMedGoogle Scholar
• 51 Willemsen R, Hoogeveen-Westerveld M, Reis S et al.. The FMR1 CGG repeat mouse displays ubiquitin-positive intranuclear neuronal inclusions; implications for the cerebellar tremor/ataxia syndrome.  Hum Mol Genet. 2003;  12 (9) 949-959
  CrossrefPubMedGoogle Scholar
• 52 Todd P K, Paulson H L. RNA-mediated neurodegeneration in repeat expansion disorders.  Ann Neurol. 2010;  67 (3) 291-300
  CrossrefPubMedGoogle Scholar
• 53 Brouwer J R, Huizer K, Severijnen L A et al.. CGG-repeat length and neuropathological and molecular correlates in a mouse model for fragile X-associated tremor/ataxia syndrome.  J Neurochem. 2008;  107 (6) 1671-1682
  CrossrefPubMedGoogle Scholar
• 54 Loesch D Z, Bui Q M, Huggins R M, Mitchell R J, Hagerman R J, Tassone F. Transcript levels of the intermediate size or grey zone fragile X mental retardation 1 alleles are raised, and correlate with the number of CGG repeats.  J Med Genet. 2007;  44 (3) 200-204
  PubMedGoogle Scholar
• 55 Nolin S L, Brown W T, Glicksman A et al.. Expansion of the fragile X CGG repeat in females with premutation or intermediate alleles.  Am J Hum Genet. 2003;  72 (2) 454-464
  CrossrefPubMedGoogle Scholar
• 56 Zhong N, Yang W, Dobkin C, Brown WTCINAJHGJ. Fragile X gene instability: anchoring AGGs and linked microsatellites.  Am J Hum Genet. 1995;  57 (2) 351-361
  PubMedGoogle Scholar
• 57 Weisman-Shomer P, Cohen E, Fry M. Interruption of the fragile X syndrome expanded sequence d(CGG)(n) by interspersed d(AGG) trinucleotides diminishes the formation and stability of d(CGG)(n) tetrahelical structures.  Nucleic Acids Res. 2000;  28 (7) 1535-1541
  CrossrefPubMedGoogle Scholar
• 58 Napierala M, Michalowski D, de Mezer M, Krzyzosiak W J. Facile FMR1 mRNA structure regulation by interruptions in CGG repeats.  Nucleic Acids Res. 2005;  33 (2) 451-463
  CrossrefPubMedGoogle Scholar
• 59 Bione S, Benedetti S, Goegan M et al.. Skewed X-chromosome inactivation is not associated with premature ovarian failure in a large cohort of Italian patients.  Am J Med Genet A. 2006;  140 (12) 1349-1351
  PubMedGoogle Scholar
• 60 Spath M A, Nillesen W N, Smits A P et al.. X chromosome inactivation does not define the development of premature ovarian failure in fragile X premutation carriers.  Am J Med Genet A. 2010;  152A (2) 387-393
  CrossrefPubMedGoogle Scholar
• 61 Rodriguez-Revenga L, Madrigal I, Badenas C, Xunclà M, Jiménez L, Milà M. Premature ovarian failure and fragile X female premutation carriers: no evidence for a skewed X-chromosome inactivation pattern.  Menopause. 2009;  16 (5) 944-949
  CrossrefPubMedGoogle Scholar
• 62 Hundscheid R D, Sistermans E A, Thomas C M et al.. Imprinting effect in premature ovarian failure confined to paternally inherited fragile X premutations.  Am J Hum Genet. 2000;  66 (2) 413-418
  CrossrefPubMedGoogle Scholar
• 63 Tassone F, Hagerman R J, Chamberlain W D, Hagerman P J. Transcription of the FMR1 gene in individuals with fragile X syndrome.  Am J Med Genet. 2000;  97 (3) 195-203
  CrossrefPubMedGoogle Scholar
• 64 Hunter J E, Epstein M P, Tinker S W, Charen K H, Sherman S L. Fragile X-associated primary ovarian insufficiency: evidence for additional genetic contributions to severity.  Genet Epidemiol. 2008;  32 (6) 553-559
  CrossrefPubMedGoogle Scholar
• 65 Miano M G, Laperuta C, Chiurazzi P, D'Urso M, Ursini M V. Ovarian dysfunction and FMR1 alleles in a large Italian family with POF and FRAXA disorders: case report.  BMC Med Genet. 2007;  8 18
  PubMedGoogle Scholar
• 66 Bontekoe C J, Bakker C E, Nieuwenhuizen I M et al.. Instability of a (CGG)98 repeat in the Fmr1 promoter.  Hum Mol Genet. 2001;  10 (16) 1693-1699
  CrossrefPubMedGoogle Scholar
• 67 Entezam A, Biacsi R, Orrison B et al.. Regional FMRP deficits and large repeat expansions into the full mutation range in a new fragile X premutation mouse model.  Gene. 2007;  395 (1-2) 125-134
  CrossrefPubMedGoogle Scholar
• 68 Peier A M, Nelson D L. Instability of a premutation-sized CGG repeat in FMR1 YAC transgenic mice.  Genomics. 2002;  80 (4) 423-432
  CrossrefPubMedGoogle Scholar

Shannon D SullivanM.D. Ph.D. 

Washington Hospital Center

110 Irving St. NW, Suite 217–72, Washington, DC 20010

Email: Shannon.D.Sullivan@Medstar.net